Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Myeloid 1Head & Neck 1Gastrointestinal 1CNS 1

Conditions

Thyroid Neoplasms 1Lung Neoplasms 1Histiocytosis 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Brain Neoplasms 1

Interventions

Thiotepa 3Melphalan 3Cyclophosphamide 3fludarabine phosphate 2fludarabine 2Busulfan 2Alemtuzumab 2Whole-Body Irradiation 1Therapeutics 1Tacrolimus 1Panitumumab 1PLX8394 1Muromonab-CD3 1Methylprednisolone Hemisuccinate 1Methylprednisolone 1Immunotherapy 1IFL protocol 1Gemcitabine 1Drug Therapy 1Cetuximab 1Antilymphocyte Serum 1Antibodies 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Histiocytosis × IFL protocol × Myeloid × Clear all
NCT05786924 2026-04-21

Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies

Servier

Phase 1/2 Recruiting
554 enrolled
CNSGastrointestinalHead & NeckMyeloidThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Thyroid Neoplasms, Colorectal Neoplasms, Histiocytosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡